MedTrace Logo

Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia

NCT01391403 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2016-07-12

No results posted yet for this study

Summary

This study will determine the effectiveness of artemisinin plus risperidone in improving symptoms and cognitive disturbances and in Chinese people with schizophrenia. The study addresses the Toxoplasma infection hypothesis of schizophrenia.

Conditions

Interventions

DRUG

Artemisinin

400 mg/day

OTHER

Placebo

400mg/day

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Beijing HuiLongGuan Hospital

    lead OTHER

Principal Investigators

  • Lian Y Cao, MD · Beijing HuiLongGuan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-04-30
Completion
2011-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01391403 on ClinicalTrials.gov